Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
May 21, 2014
FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype
David J DeGraff, Magdalena M Grabowska, Tom C Case, et al.
Scientific Reports
|
December 8, 2016
FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
Joshua I Warrick, Vonn Walter, Hironobu Yamashita, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
Monika Joshi, Leonard Tuanquin, Junjia Zhu, et al.
Plos One
|
May 17, 2012
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation
David J DeGraff, Peter E Clark, Justin M Cates, et al.
Molecular Endocrinology (Baltimore, Md.)
|
May 8, 2014
NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression
Magdalena M Grabowska, Amicia D Elliott, David J DeGraff, et al.
Genome Biology
|
April 16, 2021
Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer
Tejaswi Iyyanki, Baozhen Zhang, Qixuan Wang, et al.
Oncogene
|
October 23, 2019
Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer
Vasty Osei-Amponsa, Jenna M Buckwalter, Lauren Shuman, et al.
Nature Communications
|
March 28, 2026
FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment
Lourdes Brea, Hongshun Shi, Viriya Keo, et al.
Urology
|
May 25, 2016
Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract
Jay D Raman, Joshua I Warrick, Carla Caruso, et al.
Molecular Oncology
|
August 7, 2013
SPARCL1 suppresses metastasis in prostate cancer
Yuzhu Xiang, Qingchao Qiu, Ming Jiang, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
May 21, 2014
FOXA1 deletion in luminal epithelium causes prostatic hyperplasia and alteration of differentiated phenotype
David J DeGraff, Magdalena M Grabowska, Tom C Case, et al.
Scientific Reports
|
December 8, 2016
FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
Joshua I Warrick, Vonn Walter, Hironobu Yamashita, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
Monika Joshi, Leonard Tuanquin, Junjia Zhu, et al.
Plos One
|
May 17, 2012
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation
David J DeGraff, Peter E Clark, Justin M Cates, et al.
Molecular Endocrinology (Baltimore, Md.)
|
May 8, 2014
NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression
Magdalena M Grabowska, Amicia D Elliott, David J DeGraff, et al.
Genome Biology
|
April 16, 2021
Subtype-associated epigenomic landscape and 3D genome structure in bladder cancer
Tejaswi Iyyanki, Baozhen Zhang, Qixuan Wang, et al.
Oncogene
|
October 23, 2019
Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer
Vasty Osei-Amponsa, Jenna M Buckwalter, Lauren Shuman, et al.
Nature Communications
|
March 28, 2026
FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment
Lourdes Brea, Hongshun Shi, Viriya Keo, et al.
Urology
|
May 25, 2016
Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract
Jay D Raman, Joshua I Warrick, Carla Caruso, et al.
Molecular Oncology
|
August 7, 2013
SPARCL1 suppresses metastasis in prostate cancer
Yuzhu Xiang, Qingchao Qiu, Ming Jiang, et al.
Page
of 7